Table 2: Characteristics of studies evaluating the role of FGS with 5-ALA on extents of resection ± post-operative survival in HGGs.
Study |
Population |
Intervention |
Control |
% of patients who received CRET |
Mean EoR (%) |
Median survival since intervention (months) |
Significant survival benefit vs. control (months) |
||||
Intervention |
Control |
Intervention |
Control |
OS |
PFS |
OS |
PFS |
||||
Della Puppa, et al. [22]
|
HGGs in eloquent areas only |
FGS with functional mapping and iMRI (N = 31) |
- |
74 |
- |
98.9 |
- |
- |
- |
-
|
- |
Schatlo, et al. [23] |
HGGs |
FGS and iMRI (N = 55) |
No iMRI (N = 145) |
45 |
30 |
- |
- |
17.9 |
10.6 |
None |
None |
Sharma, et al. [24] |
HGGs |
FGS and iMRI (N = 37) |
- |
97.3 |
- |
99.9 |
- |
31.2 |
- |
- |
- |
Quick-Weller, et al. [25] |
Recurrent HGGs only |
FGS and iMRI (N = 7) |
- |
100 |
- |
100 |
- |
7.6 |
- |
- |
- |
Archavlis, et al. [26] |
Recurrent HGGs only |
FGS, brachytherapy and temozolamide chemotherapy (N = 17) |
Temozolamide chemotherapy only (N = 17) |
59 |
- |
- |
- |
8 |
7 |
3 |
3.5 |
Coburger, et al. [27] |
HGGs |
FGS and iMRI (N = 33) |
iMRI only (N = 33) |
75.8 |
- |
99.7 |
97.4 |
18 |
6 |
None |
None |
Díez Valle, et al. [18] |
HGGs |
FGS and iMRI (N = 36) |
- |
83.3 |
- |
99.8 |
- |
11.8 |
- |
- |
- |
Piquer, et al. [20] |
HGGs |
FGS and iMRI (N = 27) |
- |
79.3 |
- |
- |
- |
- |
- |
- |
- |
HGG: High-Grade Gliomas (WHO grade 3); FGS: Fluorescence-Guided Surgery (with 5-ALA); Imri: Intra-Operative MRI; CRET: Complete Resection of Enhancing Tumour; EoR: Extent of Resection; OS: Overall Survival from treatment; PFS: Progression-Free Survival (time between surgery and development of new symptoms or progression of tumour on imaging)